East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Levothyroxine Sodium Tablets USP, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. Aurobindo Pharma’s Levothyroxine Sodium Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Synthroid Tablets manufactured by AbbVie Inc.

Levothyroxine Sodium Tablets are indicated for the:

• Treatment of Hypothyroidism
• Treatment of Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression.